The anti-IGFBP7 sdAb developed in this study was demonstrated to bind specifically to both human and mouse GBM vessels in brain tissue sections and to tumour vessels after systemic injection in a mouse model of orthotopic glioblastoma. This evidence concerns the gene IGFBP7 and neoplasm.